Auburn presents a variety of technologies developed by the university at the Alabama BIO conference

Auburn presents a variety of technologies developed by the university at the Alabama BIO conference

Body of the article

Auburn University recently attended the Alabama BIO conference at the Grand Bohemian Hotel in Mountain Brook, showcasing seven of its biotech research developments.

BIO Alabama is the trade organization for the state life science industry. This year’s event, the first meeting after a six-year hiatus due in part to the COVID-19 pandemic, was attended by around 200 scientists and their research developments from April 25-26.

Melinda Richter, Johnson & Johnson’s Global Head of Innovation, was keynote speaker on this year’s theme, “Building Alabama’s Biohorizons,” which focused on the future of industry participation in Alabama’s innovation economy.

Auburn’s presentations included:

  • Vivosphere Cell Encapsulation Technology Platform for Drug Development and Discovery (Elizabeth Lipke; presented by co-inventor Yuan Tian) – This is a more accurate and accurate 3D cell encapsulation method and device for drug screening, bioinks and regenerative medicine cheap.

  • CD47 targeted anticancer immunotherapy (James Gillespie, joint project with VCOM) – Development of an anticancer treatment that could replace CD47 targeted immunomodulatory therapies.

  • Computational tool to accelerate the discovery of beneficial natural compounds (Angela Calderon and Cheryl Seals; presented by Kabre Heck and Muhammad Gulfam) – A collaborative project on an automated method for analyzing mass spectrometry data to identify potential bioactive compounds in mixtures complex.

  • Bacteria engineered for the production of biofuels and other compounds (Yi Wang) – Engineering of bacteria to express record levels of butanol for biofuels or other industrial applications or to express record levels of butyl acetate for use in food, consumer goods or industrial processes.

  • Computationally Designed Compounds for the Treatment of Alzheimer’s Disease (Raj Amin; presented by Ian Steinke and Fajar Wibowo) – A custom-designed therapeutic compound for the treatment of Alzheimer’s disease without the side effects seen with other drugs in this class.

  • Gene Therapy Vectors for the Therapeutic Treatment of Neurological Diseases (Doug Martin) – Engineered AAV vectors for the treatment of neurological diseases such as rabies.

  • Medical device to improve the diagnosis and monitoring of neuropathy in diabetic patients (Michael Zabala and Thomas Burch; presented by co-inventor Kenny Brock, VCOM) – A medical device to accurately monitor and measure sensory loss in diabetic patients. (Jon Commander is also a co-inventor and is with VCOM.)

BIO Alabama is the leading proponent of Alabama’s bioeconomy. The organization represents the state nationally and internationally, promoting intellectual and innovative capital to make Alabama a prime place to invest, initiate and grow in biosciences.

Alabama’s life sciences industry provides a $ 7.3 billion impact on the state’s economy, according to data from BIO Alabama. Auburn has been attending BIO Alabama events for several years.

“As the Presenting Sponsor for this year’s BIO Alabama conference, Auburn University had an important opportunity to showcase some of our latest technologies during an industry turnaround session,” said Bill Dean, Director executive of the Auburn Research and Technology Foundation.

“Auburn’s participation in events such as the Alabama BIO conference speaks to our role in the growth of the region’s bioeconomy and demonstrates our commitment to the bio-sector in the form of industrial collaboration and partnerships that will advance research and impact quality of life. throughout the state “.

(Written by Mitch Emmons)

.

Leave a Comment

Your email address will not be published.